GC Cell said on Friday that it signed an agreement with IQVIA, the world's largest contract research organization (CRO), to conduct a multicountry phase 1 clinical trial of its CAR-NK cell therapy targeting solid tumors, AB201.Accordingly, GC Cell plans to conduct multicountry clinical trials of AB-
Samsung Electronics said on Thursday that its Galaxy Watch series recently received approval from the Ministry of Food and Drug Safety (MFDS) for a feature that supports early detection of sleep apnea.Sleep apnea is a condition in which breathing stops during sleep, interferes with the supply of oxy
Lotte Healthcare said on Thursday that it established a joint management system for Theragen Health, a company established with Theragen Bio, whereby Lotte Healthcare's Executive General Manager Woo Woong-jo and Theragen Bio CEO Hwang Tae-soon will serve as co-chairmen.Theragen Health, a subsidiary
Tax losses and criminal activity are often highlighted as the main impacts of the illicit tobacco trade but the health impacts of the illicit tobacco trade are often overlooked. The illicit tobacco trade can have ripple effects on health as treating tobacco-related diseases imposes heavy financial b
Seoul National University Bundang Hospital (SNUBH) announced that its researchers have secured 1.6 billion won ($1.18 million) in research funding for conducting clinical research using artificial intelligence (AI) to select the best embryos for implantation during in vitro fertilization (IVF).Profe
Despite Korea reducing Covid-19 emergency response levels, immunology experts elaborated that the only way to keep the virus under control was through seasonal updated vaccination to adapt to the mutating virus. In response, Moderna Korea held a press conference on Thursday to share data on the clin
GC Biopharma said on Thursday that its drug candidate to treat thrombotic thrombocytopenic purpura (GC1126A) has received orphan drug designation from the U.S. FDA on Sept. 27.Accordingly, the orphan drug designation will provide tax breaks on research and development expenses, exemption from permit
Lotte Biologics said on Wednesday that it signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZ) to build three bioprocessing plants in Songdo, Incheon, by 2030.The plants will be situated at Songdo International Business District, Block KI20 in Zone 11, and will have
GSK Korea said on Wednesday that it appointed Maurizio Borgatta as its new general manager as of Oct. 1.Borgatta will fill the shoes of outgoing GSK Korea General Manager, Rob Kempton, who has led GSK Korea since 2020. Subsequently, Kempton will serve as Head of the Vaccines Market in Europe.Since j
Handok said on Wednesday that it entered into a strategic partnership with global biopharmaceutical company Sobi to strengthen its rare disease business. Sobi, a Swedish biopharmaceutical specializing in rare diseases, provides innovative therapies in hematology, immunology, and specialty care, with
Celltrion said on Wednesday that it received approval from the FDA for its 80 mg and 20 mg dosage forms of Yuflyma, a biosimilar referencing Abbvie's Humira (ingredient: adalimumab), adding to the existing approval for the 40 mg dose. Humira, the original medicine, is prescribed primarily for autoim
Roche Korea said on Wednesday that its oral treatment for spinal muscular atrophy (SMA), Evrysdi (ingredient: risdiplam), obtained health insurance coverage from Oct.1.Accordingly, Evrysdi will be covered for patients with 5q SMA with a confirmed genetic diagnosis of a deletion or mutation in the 5q
In a country where speed is emphasized as a way of life, it is uncommon to talk about Korea being slow at doing something. However, this is the case with malaria treatment in the country, as Korean physicians lack experience due to the relatively low annual caseload.Unlike Korea, malaria generally h
Handok said on Wednesday that it submitted an IND plan for a global phase 2/3 clinical trial of HDB001A, a biliary tract cancer drug candidate, to the Ministry of Food and Drug Safety (MFDS). The global phase 2/3 study of HDB001A will enroll 150 patients at more than 35 sites in Korea and overseas.
Bridge Biotherapeutics announced on Tuesday that it will discontinue the development of BBT-176, a drug candidate for non-small cell lung cancer (NSCLC), and BBT-212, another candidate for fundus disease.Instead, the company stated it would focus on BBT-877 and BBT-207, candidates for idiopathic pul
Severance Hospital said on Tuesday that it successfully transplanted cell therapy products derived from embryonic stem cells into the brain of a patient to treat Parkinson's disease.The investigational drug is a midbrain dopamine neural progenitor cells differentiated from human embryonic stem cells
With a dream to revolutionize the field of diagnostics, Eone Diagnomics Genome Center (EDGC) is charting a way forward to use methylation patterns as a way to encourage early disease detection, starting with cancer and hoping to expand to neurodegenerative diseases such as Alzheimer's disease and in
Philips Korea said on Tuesday that it installed its digital pathology solution at Konyang University Hospital, making the hospital the first university hospital in the central part of Korea equipped with a full digital pathology system.Philips IntelliSite Pathology Solution is a digital pathology im
EyeGene said on Friday in a public filing that its phase 2 clinical trial of EG-Myocin, a drug candidate for the treatment of myocardial ischemia and reperfusion injury, failed to show statistically significant changes in myocardial infarction size. The study explored the effectiveness and safety of
Celltrion Healthcare said on Monday it won bids in major European countries for three of its anti-cancer biosimilars, Truxima (ingredient: rituximab), Herzuma (ingredient: trastuzumab), and Vegzelma (ingredient: bevacizumab), since switching to direct sales. On the same day, Celltrion also announced